Expert framework defines core competencies for uveal melanoma plaque brachytherapy

An expert training framework defines the clinical, dosimetric, procedural and radiation safety competencies required for independent ocular plaque brachytherapy practice.

KEY POINTS

  • This educational review proposes four core competency domains for radiation oncologists training in plaque brachytherapy for uveal melanoma: brachytherapy physics, radiobiology and radiation safety; evidence-based patient selection; treatment planning and delivery; and post-treatment management. The framework builds on existing ABS/GEC-ESTRO training recommendations and emphasizes that independent practice requires documented clinical competence, multidisciplinary collaboration and hands-on experience rather than observation alone.
  • Radionuclide selection is a fundamental component of training. Iodine-125 remains commonly used for ocular plaque brachytherapy, particularly in the United States, while ruthenium-106 has an established role in European practice; palladium-103 is another relevant option. Photon-emitting sources and beta-emitting plaques differ in tissue penetration, depth-dose gradients and surrounding OAR exposure, but no prospective comparative trial has established superiority of one radionuclide in clinical control, toxicity or survival.
  • Patient selection requires close collaboration with an ocular oncologist and familiarity with fundus photography, B-scan ultrasonography, ultrasound biomicroscopy and optical coherence tomography. Tumor basal diameter, apical thickness, anatomical location and distance from the optic nerve or fovea influence plaque suitability. The framework discusses treatment across selected AJCC T1–T4 categories, while extraocular extension classified as T4e, lesions exceeding plaque limitations, and painful eyes without serviceable vision may contraindicate plaque therapy.
  • Appropriate plaque geometry is essential for target coverage. For conventional iodine-125 plaques, a commonly used approach provides approximately 2 mm of circumferential margin, making the plaque diameter 4 mm larger than the tumor basal diameter. Juxtapapillary tumors may require notched or slotted plaques, and ophthalmic ultrasound can help verify intraoperative positioning. Trainees must understand how even small placement errors can affect tumor coverage and dose to the optic disc, fovea and surrounding ocular structures.
  • Prescription practices vary by isotope and institution. The historical COMS prescription was 85 Gy, while published iodine-125 plaque prescriptions commonly range from 70 to 100 Gy to the tumor apex, with selected centers reporting reduced prescriptions of 63–70 Gy. Typical reported dose rates are 0.60–1.05 Gy/h for iodine-125 and 0.44–0.61 Gy/h for palladium-103. Radiation oncologists must understand prescription depth, apex versus base dose, plaque shielding, TG-43 calculation assumptions and potential deviations introduced by tissue heterogeneity or plaque construction.
  • Safe delivery requires defined responsibilities across the radiation oncologist, ocular oncologist and medical physicist. Critical steps include radionuclide source verification, independent treatment-plan checks, confirmation of seed loading and plaque geometry, intraoperative placement assessment, documentation of implantation and removal times, and radiation surveys before and after treatment. Because plaques can remain implanted for several days, training must also include radiation protection for patients, families and clinical staff, including precautions around children and pregnant individuals.
  • Training extends beyond plaque removal to long-term disease monitoring and toxicity management. Historical COMS experience demonstrated approximately 90% five-year tumor control and eye retention in selected medium-sized tumors, while ruthenium-106 series report local control around 80–90%, with higher rates in selected modern cohorts. The framework describes follow-up commonly performed every 3–4 months until tumor regression, every six months through five years, and annually thereafter, with attention to retinopathy, maculopathy, cataract, optic neuropathy, neovascular glaucoma and metastatic surveillance informed by molecular risk markers such as 15-gene expression profile and PRAME.

CLINICAL TAKEAWAY

Plaque brachytherapy for uveal melanoma is a specialized multidisciplinary procedure requiring expertise that extends well beyond conventional radiotherapy planning, particularly in ocular anatomy, source selection, surgical coordination, dosimetry and radiation safety. This framework provides a structured basis for training and credentialing radiation oncologists, but should be understood as an educational competency document rather than new evidence favoring a specific isotope, prescription dose or treatment strategy.

SOURCE

Brachytherapy

Browse more research Suggest a correction